본문으로 건너뛰기
← 뒤로

Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression.

1/5 보강
Nature communications 📖 저널 OA 95.7% 2021: 2/2 OA 2022: 3/3 OA 2023: 3/3 OA 2024: 21/21 OA 2025: 202/202 OA 2026: 188/210 OA 2021~2026 2026 Vol.17(1) OA
Retraction 확인
출처

Cuminetti V, Boet E, Heugel M, Konieczny J, Bernal A, Gomez MJ

📝 환자 설명용 한 줄

Despite intriguing roles for the Succinate receptor (Sucnr1) in inflammation, few studies have explored its role in hematopoiesis.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Cuminetti V, Boet E, et al. (2026). Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression.. Nature communications, 17(1). https://doi.org/10.1038/s41467-026-68906-2
MLA Cuminetti V, et al.. "Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression.." Nature communications, vol. 17, no. 1, 2026.
PMID 41644523 ↗

Abstract

Despite intriguing roles for the Succinate receptor (Sucnr1) in inflammation, few studies have explored its role in hematopoiesis. Here, we show that low SUCNR1 represents a marker for reduced overall and progression-free survival in acute myeloid leukemia (AML) patients. Succinic acid, which displays Sucnr1-dependent and independent effects, promotes disease in mouse models of pre-leukemic myelopoiesis, AML and AML xenografts, expressing low SUCNR1. In vivo global or hematopoietic deletion of Sucnr1 induces expansion of hematopoietic stem and progenitor cells (HSPC) and hematopoiesis, whilst Sucnr1-tomato HSPC display restricted engraftment potential. Mechanistically, activation of Sucnr1 counterbalances the stimulatory effect of intracellular succinate in HSPC and preserves HSPC transcriptional programs via control of S100a8/S100a9. Blocking S100a9 with tasquinimod rescues the defects of Sucnr1 knock-out mice, and combined with a potent Sucnr1 agonist shows therapeutic value in AML mice. In AML xenografts, single-cell RNA-sequencing reanalyses confirm SUCNR1 as a therapeutic vulnerability in patients. Together, Sucnr1 signaling restricts hematopoiesis at least partially through HSPC and via control of S100a8/S100a9. Its dysregulation emerges as contributor to malignancy that opens therapeutic avenues for AML patients.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기